Reproduction studies have been done in rats and mice at doses up to moderately maternally toxic doses (for example, 200 mg/kg/day).

This drug is categorized as a pregnancy category B drug. īecause limited data in patients with renal GFR Label. Hepatotoxicity has been observed in rare cases.ĭue to the act that azithromycin is mainly eliminated by the liver, caution should be observed when azithromycin is given to patients with decreased hepatic function. Macrolide resistance is also an ongoing issue. Possible major adverse effects include cardiovascular arrhythmias and hearing loss. Other infections including odontogenic infections, bartonella infections, toxoplasmosis, babesiosisĪzino is also used to associated treatment for these conditions:Īcute Bacterial Sinusitis (ABS), Acute Otitis Media, Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Streptococcal tonsillitis, Tonsillitis bacterial, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis Prophylaxis against a-hemolytic (viridans group) streptococcal bacterial endocarditis Mild or moderate typhoid due to multiple-antibacterial resistant organisms

Genital ulcer disease in men due to Haemophilus ducreyi (chancroid) Sexually transmitted diseases, especially in the treatment of non-gonococcal urethritis and cervicitis due to Chlamydia trachomatis Skin and soft tissue infections including cellulitis, pyoderma, erysipelas, wound infections Lower respiratory tract infections including bronchitis, acute bacterial exacerbations of chronic obstructive pulmonary Upper respiratory tract infections including sinusitis, pharyngitis and tonsillitis

Azino ru